Mirdametinib (pd-0325901) oral capsule or dispersible tablet (DrugBank: PD-0325901)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03962543 (ClinicalTrials.gov) | September 6, 2019 | 12/4/2019 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity | Plexiform Neurofibroma;Neurofibromatosis Type 1 (NF1) | Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet | SpringWorks Therapeutics, Inc. | NULL | Recruiting | 2 Years | N/A | All | 100 | Phase 2 | United States |